

tendo

**Innovative
robotics**
with the potential
to change the
lives of people
with disabilities



INVITATION TO ACQUIRE UNITS IN TENDO AB

BEFORE PLANNED LISTING ON SPOTLIGHT STOCK MARKET

IMPORTANT INFORMATION

All investments in securities are associated with risk-taking. The prospectus for Tendo AB ("Tendo" or "the Company") contains a description of potential risks which are associated with the Company's operations and its securities. Before an investment decision can be made, these risks together with the other information in the complete prospectus, should be carefully read. The prospectus is available for download at the Company's (www.tendoforpeople.se) and Sedermera Corporate Finance AB's (www.sedermera.se) respective websites.



Tendo develops **medical robotic aids**, initially for people with disabilities in the hands.

Tendo OneGrip, which is the Company's first product, is a glove with a so-called integrated exoskeleton (a support structure on the outside of the body) which assists people with limited hand function as a result of a spinal cord injury ("SCI"). The product is minimalistic in the design and controlled completely intuitively by the body's own actual movements, while at the same time being able to assist a movement to which the body itself cannot respond to. Thus, Tendo OneGrip helps the user to grasp, hold and let go of various objects.

People who have disabilities in the hands as a result of a spinal cord injury, are today offered a personal assistant to cope with everyday activities. In some cases, complicated surgical procedures with a long rehabilitation period are also offered, and for some, these only lead to minor improvement. Currently there is no equivalent robotic aid, like Tendo OneGrip, which solves the complex needs that an SCI patient has. Therefore, the Board of Tendo considers that there is a need for an aid adapted to the patient group, which can increase independence and at the same time contribute to a significantly improved quality of life.

According to the board, the Company's future target group, individuals with limited hand function due to e.g. age, stroke, MS and RA, also has a need for a product like Tendo OneGrip. This is based on the fact that today's alternatives are usually large and bulky with lack of design and appearance. Tendo OneGrip solves this by being minimalistic in the design, comfortable to wear all day, feeling like a natural part of the body, and at the same time being hygienic.

With the sight set on market launch in 2023

Tendo OneGrip is currently in the final stages of the development process to be ready for launch in the near future. In 2022, the product will go through an optimization and evidence phase, two important steps to reach market launch. The Company's goal is to market launch Tendo OneGrip in the beginning of 2023. Tendo initially plans to sell the product in countries with established national insurance systems, suitable for Tendo's business model. Denmark, where the Company has established collaborations with, in particular, medical experts within the field is assessed to be the initial market together with Sweden and Norway. In the long term, sales will also take place in the United States, Japan and the rest of Europe, with start 2024.

The Company is now carrying out a capitalization prior to listing on Spotlight Stock Market, which can initially supply the Company with approx. SEK 18.75 million (before deductions for issue costs and compensation to bridge lenders), with the main purpose of financing the planned market launch of Tendo OneGrip during 2023. In addition to shares, the issue of units also includes warrants of series TO 1, which at full exercise to the highest exercise price during Q2 2023, will add a further maximum of approx. SEK 11.25 million before issue costs.



"Tendo operates with the mission to give back independence to people living with a disability, while contributing to solving the global health challenges."



INVESTMENT HIGHLIGHTS

Unique technology with the potential to change the lives of people with disabilities

With innovative robotics, Tendo has developed the soft exoskeleton Tendo OneGrip – a minimalistic and active glove whose task is to assist the hand function for individuals with impaired grip function due to a spinal cord injury. With the help of smart sensors, the product can assist a movement that a paralyzed body part itself cannot react to. This system is, according to the Board, revolutionary as it contributes to life-changing opportunities for the user. Today, according to the Board's assessment, no other product on the market can satisfy the needs that Tendo OneGrip meets.

The product is developed and validated by potential users


The need and above all the benefit that Tendo OneGrip provides, has become clear during several of the workshops that Tendo has performed together with potential users. By involving the users from the start, the Company has been able to develop the product in accordance with their requirements and needs. Thanks to Tendo OneGrip, a user could for example carry out his daily activities without a personal assistant for the first time in 20 years.

Awards and collaborations with distinguished parties

Tendo has since the start in 2016 received several awards, participated in several conferences, and been supported by various parties in robotics, both financially and technically. The Company is part of Odense Robotics, which is one of the world's largest robotics clusters, and has previously been part of Odense Robotics StartUp Hub whereby Tendo was supported with business development, investment contacts, advice and networks. In addition, Tendo was, in the end of 2019, ranked as the best robotic startup in Europe, out of 200 applicants from 23 different countries. The same year, Tendo was also selected, among over 700 applicants from all over the world, to hold a symposium about the Company's technology at ISPO's (International Society for Prosthetics and Orthotics) World Congress in Japan.

Large market potential with over 50 million potential users

Today, about 600,000 people are living with a spinal cord injury in Europe, North America, and Japan, and the WHO estimates that the global annual incidence is 40-80 cases per one million inhabitants.¹ A spinal cord injury is highly individual and therefore, Tendo OneGrip must be specially adapted to each individual in the target group. The Company's technology is internationally scalable, and in the long run, Tendo intends to adapt the product to a wider range of target groups that do not require special adaptation, e.g. elderly, stroke, rheumatism and MS patients. This can enable mass production and result in a potential market of about 50 million users in Europe, North America, and Japan alone. The trend also points clearly towards more robot technology in health care, e.g. exoskeleton and robotic prosthetics. Robot technology will play an important part of relieving an already often overburdened healthcare system.



Tendo OneGrip will be launched on the Scandinavian market during the beginning of 2023. The Company is also preparing for global expansion and will during 2024 start sales in i.a. the United States.

Great interest from the industry

Healthcare staff at clinics in Denmark, Sweden and Norway, has shown interest in Tendo's product and validated it at executed workshops. Several of these clinics have also showed interest in continued cooperation, which i.a. has been confirmed with a so-called letter of intent with Rigshospitalet's specialist clinic for spinal cord injuries in Hornbæk, Denmark. In addition, global players in the orthotic and prosthetic industry have showed an interest in including Tendo OneGrip in their product portfolios.

Strong protection against competitors

The Company has two patent families that are deemed to protect Tendo's product against potential competitors, as well as for future market expansion. Tendo's first patent family protects the Company's versatile and energy efficient mechanical solution, which enables a light and flexible product. The Company's other patent family protects the intuitive control of Tendo's product.

Opportunity for diversified sources of income

The Company's business model entails two different revenue streams – direct and indirect sales. Direct sales are handled by Tendo and refers to nearby markets. Indirect sales take place through partner agreements and is expected to be relevant in larger countries, such as the United States.

The possibilities with the Company's technology and mechanical patent extend beyond the Tendo OneGrip, and can be applied on more body parts, e.g. knee, foot and shoulder. Therefore, in the future, Tendo intends to expand its product portfolio with more wearable technical innovations for more body parts, expected to further broaden Tendo's market.

Experienced management and Board

The management and Board of Tendo have solid experience in i.a. design, product development, robotics, electronics, orthopedic technology and business development. Their knowledge and expertise are beneficial for the Company's future development.


¹ <https://www.who.int/news-room/fact-sheets/detail/spinal-cord-injury>

OBJECTIVES

Tendo was founded in 2016 and has, despite its short company history, achieved several important milestones. The Company has i.a. established a global network, which Tendo considers to be beneficial in the market launch of Tendo OneGrip. Below is a selection of the Company's operational and financial objectives for the upcoming years.

2022

- Q2** • Listing on Spotlight Stock Market.
- Recruitment of project manager and mechanical engineer.



- Q3** • Provide quality management systems that follows ISO 13485.*
- Q4** • Complete literature study.
- Complete usability study.

2023

- Q1** • Market launch of Tendo OneGrip in Scandinavia.
- Q2** • Exercise of warrants, which can provide the Company a maximum of approx. SEK 11.25 million.
- Begin clinical study.
- Further development of existing product.

- Q3** • Begin global expansion**, i.a. enter agreements with potential partners.

* Ensures that Tendo as an organization works in a correct way to manufacture medical devices, and includes, for example, document management, process description, supplier management and product development routines for all stages of development, production, and follow-up after sales.

** Refers to initial work to enable sales in e.g. the United States, which is expected to begin in 2024.

FINANCIAL OBJECTIVES

Tendo's objective is to, one year after market introduction, be a profitable growth company. The global market for medical exoskeletons is expected to be worth approx. 1 billion USD by 2026.² Tendo aims to reach a market share of approx. 1 percent, which would correspond to a turnover of about 10 million USD. This market share is expected to increase rapidly the following year.

The Company expects to reach a positive cash flow in 2024, one year after market introduction, and generate organic sales growth about 80–110 percent per year the next three financial years, as a result of a growing market and increased market shares. Growth is then expected to be high for the foreseeable future. Furthermore, the Company's objective is to increase the short-term EBITDA margin of approx. 20–35 percent to about 60–70 percent in the medium-term.

2. <https://www.marketsandmarkets.com/Market-Reports/medical-exoskeleton-market-138546702.html>



CEO SOFIE WOGHE HAS THE WORD

"With the help of innovative robot technology, we have created a technology that can assist the hand function for individuals with an impaired grip due to a spinal cord injury."



Most of us take our hand function for granted, even though the hands are essential for doing the most basic everyday activities, such as brushing your teeth, drinking a glass of water and eating a meal. Unfortunately, this is not the case for everyone. In fact, around 50 million people in Europe, North America and Japan alone, live with limited hand function. Out of these, approx. 600,000 have been disabled as a result of a spinal cord injury, which is usually caused by a trauma (falls, car accidents and violence) but also due to illness, such as cancer. Although a large number of individuals live with limited hand function as a result of a spinal cord injury, there are currently no medical device that can solve the needs of the target group – to regain their hand function.

”

"Tendo's mission is to help as many people as possible worldwide."

I am therefore proud to introduce you to Tendo, that has developed the revolutionary product Tendo OneGrip with support from NASA, Odense Robotics, Ideon Innovation and potential users. By using innovative robot technology, we have created a technology that can assist the hand function of individuals with an impaired grip due to a spinal cord injury. Tendo OneGrip is controlled intuitively by the body's own movements and no existing grip function is required for the technology to work. Thanks to the innovative mechanics and technology in Tendo OneGrip, we believe that the product is revolutionary and, most importantly, contributes to improved quality of life for individuals with disabilities.

Since the start in 2016, Tendo has received several awards and prizes. Among other things, we have been ranked as the best robotic startup in Europe, and participated as a speaker at major conferences, e.g. at TEDxOdenseWomen and ISPO World Congress. On our journey, we also have several players with us who believe in our innovative product and have chosen to support us both financially and technically, including private investors, Vinnova, Ideon Innovation, Odense Robotics and RobotUnion. Even though we have not yet launched our product on the market, we have succeeded in establishing a global network with recognized players and researchers in the industry, which will be a big advantage when we launch Tendo OneGrip in 2023.

Tendo's mission is to help as many people as possible worldwide. That is why we work hard in order to develop more products for additional target groups. The goal is to be able to contribute to life-changing opportunities also for people living with impaired hand function as a result of e.g. age, stroke and MS, as well as people who have disabilities in other body parts, such as knees, feet and shoulders. With the need that demonstrably exist, as well as the revolutionary technology that we possess, I am convinced that Tendo has an obvious place in the MedTech industry in the future.

In the beginning of 2023, it is finally time. Tendo OneGrip will be launched and people with impaired hand function as a result of a spinal cord injury, will finally get a useful aid adapted for them. To enable the launch, we are now carrying out a capitalization prior to listing on Spotlight Stock Market, which Team Tendo is incredibly excited about. I hereby invite you to invest in our issue of units prior to listing, so that we together can give back independence to people living with disabilities, at the same time as we contribute to solving the global health challenges. Warm welcome to invest in Tendo!

Sofie Woghe
CEO Tendo AB

THE OFFER IN BRIEF

Application period

March 14 to March 28, 2022.

Offering price

SEK 13.50 per unit, which corresponds to SEK 6.75 per share. The warrants of series TO 1 are issued free of charge.

Minimum post

350 units, corresponding to SEK 4,725.

Issue volume

The total offer amounts to a maximum of approx. SEK 30 million. Of this the Company can initially be provided with approximately SEK 18.75 million (before deductions for issue costs and compensation to bridge lenders). The Company can, at a later stage, in full use of the issued warrants of series TO 1 at the highest exercise price, be provided a further maximum of approx. SEK 11.25 million (before issue costs).

Subscription commitments

Approx. SEK 14 million of the issue is covered by subscription commitments, which corresponds to approx. 74.3 percent of the initial issue volume. Remaining part of the initial part of the issue, corresponding to approximately SEK 4.75 million, is available to the public.

Number of shares before the issue

3,702,000 shares.

Valuation (pre-money)

Approx. SEK 25 million.

Scheduled first day of trading

April 6, 2022.

ISIN code for the share

SE0017486426.

Lock up

The Company's major shareholders as well as Board members and executives, whose total shareholding amounts to approx. 99.97 percent of the Company's shares, have entered into lock-up agreements corresponding to 100 percent of their respective holdings, and have thus committed not to divest or carry out other transactions with the equivalent effect as a sale over a twelve-month period, calculated from the first day of trading in the share on Spotlight Stock Market.

Warrants of series TO 1

Holders of warrants of series TO 1 have the right to, for each warrant, subscribe for one new share in the Company at a price at SEK 6.75 - 8.10 per share. The subscription price will (within the range above) be set to 70 percent of the average volume-weighted price of the share, according to the official price statistics at Spotlight Stock Market during a period of 20 trading days ending two banking days before the start of the exercise period. The exercise price will be published one to two days before the first day in the exercise period. Subscription with the support of warrants of series TO 1 can take place during the period from March 16 until April 6, 2023.

ISIN code for warrants of series TO 1

SE0017563893.

For more information about the offer
and how to apply for units in Tendo AB

Application period:
March 14 to March 28, 2022.